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Pulmonary arterial hypertension (PAH) is a fatal lung disease caused by the progressive remodeling of small pulmonary arteries (PAs). Sildenafil (SIL) can prevent the remodeling of PAs, but conventional SIL formulations have shown limited treatment efficacy for their poor accumulation in PAs. Here, glucuronic acid (GlcA)-modified liposomes (GlcA-Lips) were developed to improve the delivery of SIL to aberrant over-proliferative PA smooth muscle cells (PASMCs) via targeting the glucose transport-1 (GLUT-1), and therefore inhibiting the remodeling of PAs in a monocrotaline (MCT)-induced PAH model. GlcA-Lips encapsulating SIL (GlcA-SIL-Lips) had a size of 90 nm and a pH-sensitive drug release pattern. Immunostaining assay indicated the overexpression of GLUT-1 in PASMCs. Cellular uptake studies showed 1-fold increase of GlcA-Lips uptake by PASMCs and pharmacokinetics and biodistribution experiments indicated longer blood circulation time of GlcA-Lips and increased ability to target PAs by 1-fold after 8 h administration. Two-week treatment indicated GlcA-SIL-Lips significantly inhibited the remodeling of PAs, with a 32% reduction in the pulmonary arterial pressure, a 41% decrease in the medial thickening, and a 44% reduction of the right ventricle cardiomyocyte hypertrophy, and improved survival rate. Immunohistochemical analysis showed enhanced expression of caspase-3, after administration of GlcA-SIL-Lips, and reduced expression of P-ERK1/2 and hexokinase-2 (HK-2), and increased level of endothelial nitric oxide synthase (eNOS) and cyclic GMP (cGMP). In conclusion, targeted delivery of SIL to PASMCs with GlcA-Lips could effectively inhibit the remodeling of PAs in the MCT-induced PAH. 
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Background 
Pulmonary arterial hypertension (PAH) occurs either in idiopathic form or in association with diseases such as congenital heart malformation, connective tissue disease or human immunodeficiency virus infection. It is typically characterized by increased pulmonary vascular resistance, vascular remodeling caused syncope, dyspnea on exertion, right heart failure, and even premature death. ADDIN EN.CITE ,  The mechanism of vascular remodeling has been intensively investigated, but has not yet been completely elucidated. Currently, inducing apoptosis or suppressing proliferation of vascular cells are still the mainstay for the treatment of PAH, based on the apoptotic resistance theory. ADDIN EN.CITE 3 This theory was proposed to be involved in the hyperplasia of pulmonary vascular cells, which contributes to the formation of the neointimal lesions and medial thickening of the small pulmonary arteries (PAs). 
Conversely, several research groups have reported that inhibiting the apoptosis of endothelial cells, by up-regulating angiopoietin or through targeting delivery of antioxidant, ADDIN EN.CITE ,  allowed for the protective effect on the pulmonary vasculature regression. ADDIN EN.CITE 6-8 Central to these apparent contradicting results is the fact that pulmonary vascular remodeling exhibits spatio-temporal diversity as PAH develops, with coexistence of both proliferative vascular cells and apoptotic endothelial cells susceptible to noxious stimuli (i.e. shear stress or toxin). ADDIN EN.CITE ,  Due to the inhomogeneous distribution of vascular remodeling or cell viability conditions in small PAs, patients with intractable PAH require cell-specific or vascular compartment-specific therapies. Therefore, a pro-apoptotic therapeutic strategy that targets only to the proliferating cells, while avoiding injury to the normal or apoptotic cells, could provide an effective treatment of PAH. 
Pathologically, the progressive thickening of PAs is mainly caused from the increased proliferation and migration of smooth muscle cells (SMCs). HYPERLINK \l "_ENREF_11" \o "Rabinovitch, 2012 #3009"  ADDIN EN.CITE <EndNote><Cite><Author>Rabinovitch</Author><Year>2012</Year><RecNum>3009</RecNum><DisplayText><style face="superscript">11</style></DisplayText><record><rec-number>3009</rec-number><foreign-keys><key app="EN" db-id="wwp5zrt0ixra0oee5rvpdtaurrfw0zz59eva">3009</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Rabinovitch, M.</author></authors></contributors><auth-address>Stanford University School of Medicine, Stanford, California 94305-5162, USA. marlener@stanford.edu</auth-address><titles><title>Molecular pathogenesis of pulmonary arterial hypertension</title><secondary-title>J Clin Invest</secondary-title><alt-title>The Journal of clinical investigation</alt-title></titles><periodical><full-title>J Clin Invest</full-title><abbr-1>The Journal of clinical investigation</abbr-1></periodical><alt-periodical><full-title>J Clin Invest</full-title><abbr-1>The Journal of clinical investigation</abbr-1></alt-periodical><pages>4306-13</pages><volume>122</volume><number>12</number><keywords><keyword>Animals</keyword><keyword>Bone Morphogenetic Protein Receptors, Type II/genetics/physiology</keyword><keyword>Estrogens/metabolism</keyword><keyword>Glycolysis</keyword><keyword>Humans</keyword><keyword>Hypertension, Pulmonary/genetics/*metabolism/*physiopathology</keyword><keyword>Mutation</keyword><keyword>Pancreatic Elastase/metabolism</keyword><keyword>Receptors, Serotonin/metabolism</keyword><keyword>Serotonin Plasma Membrane Transport Proteins/metabolism</keyword><keyword>Signal Transduction</keyword><keyword>Stem Cells/metabolism</keyword></keywords><dates><year>2012</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1558-8238 (Electronic)&#xD;0021-9738 (Linking)</isbn><accession-num>23202738</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/23202738</url></related-urls></urls><custom2>3533531</custom2><electronic-resource-num>10.1172/JCI60658</electronic-resource-num></record></Cite></EndNote>11 In addition, the glycolytic activity in the lungs of PAH patients is more active than in other tissues. Restoring the oxidative phosphorylation in glycolytic SMCs could actually lead to the regression of many forms of pulmonary hypertension. ADDIN EN.CITE ,  The up-regulated glycolytic process in the lungs of PAH patients has also been confirmed by clinical studies, utilizing positron emission tomography (PET-CT) scanning. Moreover, the activation of glucose transport-1 (GLUT-1) has been identified to account for the increased uptake of glucose in those remodeled PAs. ADDIN EN.CITE 14 Therefore, the preferential uptake of glucose in the glycolytic PAs of PAH patients can be utilized as a promising noninvasive diagnostic tool to evaluate PAH development, but also be exploited to facilitate the intracellular trafficking of drugs to the site of interest. 
Accordingly, in this study, we hypothesized that GLUT-1 is overexpressed on PASMCs, and by targeting the GLUT-1, a pro-apoptotic drug could be delivered to SMCs more efficiently, inhibiting the proliferation of SMCs and reversing PAH. To verify our hypothesis, glucuronic acid (GlcA) was firstly used to modify a classic drug carrier, Liposomes (Lips), which have been recognized as one of the most successful drug delivery system for the detection and treatment of diverse diseases. More than 7 Lips based products have been approved for use in clinical applications. HYPERLINK \l "_ENREF_15" \o "Mu, 2017 #3110"  ADDIN EN.CITE <EndNote><Cite><Author>Mu</Author><Year>2017</Year><RecNum>3110</RecNum><DisplayText><style face="superscript">15</style></DisplayText><record><rec-number>3110</rec-number><foreign-keys><key app="EN" db-id="wwp5zrt0ixra0oee5rvpdtaurrfw0zz59eva">3110</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mu, Li-Min</author><author>Ju, Rui-Jun</author><author>Liu, Rui</author><author>Bu, Ying-Zi</author><author>Zhang, Jing-Ying</author><author>Li, Xue-Qi</author><author>Zeng, Fan</author><author>Lu, Wan-Liang</author></authors></contributors><titles><title>Dual-functional drug liposomes in treatment of resistant cancers</title><secondary-title>Advanced Drug Delivery Reviews</secondary-title></titles><periodical><full-title>Advanced Drug Delivery Reviews</full-title></periodical><pages>46-56</pages><volume>115</volume><keywords><keyword>Dual-functional liposomes</keyword><keyword>Multidrug resistance</keyword><keyword>ABC transporters</keyword><keyword>Cancer</keyword><keyword>Cancer stem cells</keyword></keywords><dates><year>2017</year><pub-dates><date>2017/06/01/</date></pub-dates></dates><isbn>0169-409X</isbn><urls><related-urls><url>http://www.sciencedirect.com/science/article/pii/S0169409X17300418</url></related-urls></urls><electronic-resource-num>https://doi.org/10.1016/j.addr.2017.04.006</electronic-resource-num></record></Cite></EndNote>15 Sildenafil (SIL), a selective phosphodiesterase V inhibitor, was then selected as a model drug to be encapsulated into the modified Lips. It can prevent the remodeling of PAs by inhibiting SMC proliferation as well as perivascular inflammation in MCT-induced PAH model.  ADDIN EN.CITE 16
Experimental Methods
The authors declare that all supporting data are available within the article [and its online supplementary files]. Following details are provided in the online-only Data Supplement: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(polyethylene glycol)-2000-GlcA, DSPE-PEG2000-GlcA), nanoparticle preparation, preparation of MCT model, administration of preparations to animals, isolation of PASMCs, pharmacokinetic study, in vivo 18-FDG PET, echocardiographic measurements, western blot analysis, and statistical analysis. All experiments were performed with approval from the Committee of Nanjing University Medical School for Laboratory Animal Care and Use (Nanjing, China). Most of the experimental design in vitro and in vivo refered to the Standardized Protocols described by Bonnet et al. ADDIN EN.CITE , 
Preparation of GlcA-modified Liposomes (GlcA-Lips)
Liposomes (Lips) were prepared via a hydration method. Briefly, lipid materials (S100, dioleoyl phosphoethanolamine (DOPE), cholesterol and DSPE-PEG2000-GlcA) were dissolved at a mass ratio of 18:2:8:1 in chloroform, followed by removal of the organic phase under reduced pressure. SIL-loaded Lips were prepared by mixing the empty liposomes with SIL solution (4 mg/mL) at a mass ratio of 1:29 at 55 °C for 10 min. Dye-loaded Lips were prepared in a similar way, except that the dye dissolved together with the lipid materials in chloroform prior to the hydration process. The dyes including coumarin-6 (C6), fluorescein isothiocyanate (FITC), near-infrared fluorescence (IR-783) and tetramethylindotricarbocyanine iodide (DiR) were used in the study.
Biodistribution and Lung Targeting
For the biodistribution study, the MCT-induced models (4 rats) were intravenously injected with DiR-labeled GlcA-Lips via the tail vein at a DiR dose of 0.5 mg/kg, according to the rats’ body weight. At the predetermined time points, the rats were sacrificed to collect their major organs, followed by in vivo imaging using an imaging system (IVIS Spectrum, PerkinElmer, USA).
For the quantification of SIL in the rat’s major organs, SIL preparations were intravenously injected in the MCT-induced models (4 rats) via the tail vein and at a SIL dose of 8 mg/kg, according to the rats’ body weight. At specific time intervals, the animals were sacrificed for organ collection and analysis. After the extraction processes, the SIL content was determined using the HPLC method described in the section Pharmacokinetic Study (see Data Supplement).
The co-localization of the GlcA-Lips with pulmonary arterial α-smooth muscle actin (α-SMA) in MCT-induced models was studied using Leica Corp. IX 7 fluorescence microscopy (Leica Microsystems Inc., USA). The rats received intravenous administration of IR783-Lips or GlcA-IR783-Lips at an IR783 dose of 0.5 mg/kg. 4 h after the treatment, the rats’ lungs were extracted and stored in 10% formalin for further fluorescent imaging. Briefly, formalin fixed and paraffin embedded sections were cut into 2 μm, and then blocked for 15 min with 5% FBS at room temperature. After removal of the excess serum, the sections were incubated overnight with a mouse anti-rat α-SMA monoclonal antibody at 5 µg/mL, followed by a 60 min incubation with FITC (diluted 1:200 with FITC buffer) and 15 min treatment with DAPI. 
Direct Right Ventricle Pressure Measurements
At the endpoint of the studies described above, the rat’s trachea was intubated following i.p. injection of sodium phenobarbital and mechanic ventilation was commenced. Pulmonary hemodynamic parameters were measured in the open chest by directly puncturing the right ventricle outflow tract and then advancing the catheter, that connected to a pressure transducer of an Eagle400 monitor (General Electric company, Fairfield, CT), into the pulmonary artery trunk. The right ventricle systolic pressure (RVSP) and mean pulmonary arterial pressure (PAP) were both recorded after 1 min of stabilization. 
Histopathological and Immunohistochemical Analysis of Rat Lungs and Hearts
Following the above treatments, all the rats were euthanized by exsanguination and sacrificed to collect their lungs and hearts. The right low lobes of lungs were dissected, snap-frozen and maintained at a temperature of - 80 oC until further analysis. 
Histological changes of the PAs and hearts were quantified by morphometry. Isolated lungs were inflated via the trachea with 10% formalin solution at 20 cm H2O pressure and fixed in 10% formalin. The degree of remodeling (muscularization) of small and peripheral PAs was assessed by immunohistochemical staining of 5-μm sections with an anti–α-SMA antibody (1:500 dilution; clone 1A4, Dako, Glostrup, Denmark). In each lung section, 10 small PAs (50–200 μm in diameter) and the mean area of cardiomyocytes were analyzed at a 400 magnification in a blind manner. Medial wall thickness was expressed as the sum of two points of medial thickness/external diameter × 100 (%). Slides were quenched in 3% hydrogen peroxide and the antigen was retrieved using a pressure cooker in 10 mM citrate buffer at pH 6. The slides were first blocked with serum followed by incubation with the primary antibody overnight at 4 oC. Immunodetection of Ki67 or Caspase-3 (1:100 dilution; rabbit polyclonal; Abcam, Cambridge, UK) was performed with horseradish peroxidase-conjugated anti-rabbit secondary antibody (KPL, Gaithersburg, MD, USA) and DAB stain (Dako, Glostrup, Denmark). The slides were hematoxylin counterstained. The primary antibody (Dako, Glostrup, Denmark) was omitted in the negative control for every group of slides.
Survival analysis
The rats included in the interventional protocol (6 groups with 10 rats in each group) were prospectively followed-up for survival analysis. Spontaneous deaths were counted as events. Time to event data were plotted using the Kaplan-Meier method, with differences evaluated using the Log-rank test.

Results
Preparation and Characterization of GlcA-Lips
To actively target the liposomes with SIL to GLUT-1 overexpressed in PASMCs, we used GlcA as the targeting ligand instead of Glc. Glc does not have reactive groups for direct coupling with typically available polyethylene glycol (PEG) end group functionalities (-NH2, -COOH, -SH, -N3, etc) and its conjugation to PEG requires chemical modification of the anomeric carbon by direct glycosidation with a click moiety for example (e.g. propargyl -D-glucopyranoside). On the other, GlcA is a sugar acid formed by the oxidation of the C6 carbon of glucose and is readily available. The free carboxylic group in GlcA can easily react with primary or secondary amines using carbodiimide chemistry (Figure S1A).
DSPE-PEG2000-GlcA was obtained through the amide condensation reaction, in which the carboxyl group (-COOH) of GlcA reacts with the amino group (-NH2) of DSPE-PEG-NH2 and forms a stable amide bond (-CONH-). To confirm the coupling of GlcA to DSPE-PEG2000-NH2, 1H-NMR was performed which revealed the characteristic peak of -CONH- around 5.8 ppm in the spectrum of DSPE-PEG2000-GlcA (Figure S1D).
After obtaining DSPE-PEG2000-GlcA, the lipid formulation was optimized to prepare GlcA-Lips. First, the effect of the pH-sensitive DOPE lipid on the size and entrapment efficiency (EE%) of GlcA-Lips was studied. As shown in Figure S2A, no significant changes were observed on the size and EE (%) of the GlcA-Lips with the increasing addition of DOPE to the lipid formulation, from 0 to 12.9% (w/w, compared to the weight of the total lipid). Regardless of the DOPE amount added, all obtained GlcA-Lips presented an approximate size of 90 nm, as well as an excellent drug encapsulation efficiency (EE %) of up to 85% for a highly water-soluble drug (SIL). Secondly, the effect of DOPE on the drug release from the GlcA-Lips in a pH 5.5 medium was investigated. As displayed in Figure S2B, the drug release from GlcA-Lips increased with the incorporation of DOPE, but reached its maximum when 6.9 % (w/w) DOPE was added to the formulation. Based on these observations, 6.9% (w/w) of DOPE was used in the GlcA-Lips formulations (Figure S2C). 
Characterization of the GlcA-Lips prepared with optimized formulation showed GlcA-Lips with a spherical shape (Figure S2E) and a diameter of approximately 90 nm (Figure S2D). These GlcA-Lips also showed pH-sensitive release behavior with faster drug release in acidic medium (pH 5.5 and pH 6.8), than at pH 7.4 (Figure S2F). 
Establishment of MCT-induced Models and Overexpression of GLUT-1
At the 7th, 14th, 28th days following the MCT administration in rats, comprehensive transthoracic echocardiography examinations were performed to assess the PA blood flow profile, as well as the left and right ventricle (RV) hypertrophy. The parameter of pulmonary artery blood flow accelerating time (PAAT) was closely correlated with the mean PA pressure and was utilized as a surrogate for it. HYPERLINK \l "_ENREF_19" \o "Yared, 2011 #3139"  ADDIN EN.CITE <EndNote><Cite><Author>Yared</Author><Year>2011</Year><RecNum>3139</RecNum><DisplayText><style face="superscript">19</style></DisplayText><record><rec-number>3139</rec-number><foreign-keys><key app="EN" db-id="wwp5zrt0ixra0oee5rvpdtaurrfw0zz59eva">3139</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Yared, K</author><author>Noseworthy, P</author><author>Weyman, A. E.</author><author>Mccabe, E</author><author>Picard, M. H.</author><author>Baggish, A. L.</author></authors></contributors><titles><title>Pulmonary artery acceleration time provides an accurate estimate of systolic pulmonary arterial pressure during transthoracic echocardiography</title><secondary-title>Journal of the American Society of Echocardiography Official Publication of the American Society of Echocardiography</secondary-title></titles><periodical><full-title>Journal of the American Society of Echocardiography Official Publication of the American Society of Echocardiography</full-title></periodical><pages>687</pages><volume>24</volume><number>6</number><dates><year>2011</year></dates><urls></urls></record></Cite></EndNote>19 The MCT-treated rats showed reduced PAAT, increased wall thickness and RV chamber size, as well as an insignificant effect on the size of the left ventricle, compared with the control (Figure 1A & Table S1). Altogether, these results demonstrated the success of the MCT-induced model. 
    Additionally, the expression level of GLUT-1 in both PAs and SMCs was examined via Western blot. Compared to the levels found in normal rats, the expression of GLUT-1 in the MCT-induced model was significantly higher (Figure 1B). Positive GLUT-1 immunostaining was also detected in the medial layer of the MCT-induced rats (Figure 1C). Moreover, the expression level of GLUT-1 was examined via PET-CT, as the overexpression level of GLUT-1 was assumed to be similar to the Warburg effect resulted from aerobic cytoplasmic glycolysis, which could lead to the increased 18-FDG uptake at disease sites. ADDIN EN.CITE 20 As expected, the PAH rats were shown to possess higher 18-FDG uptake in lungs and RV, compared to normal rats (Figure 1D & Table S1). Collectively, these results confirmed the overexpression of GLUT-1 in both PAs and SMCs in MCT-induced model.
Enhanced Cellular Uptake via GLUT-1 Targeting
To improve the liposome’s cellular uptake, they were modified with GlcA aimed at targeting the overexpressed GLUT-1 in SMCs. After 4 h incubation with SMCs, the cellular uptake of GlcA-C6-Lips was approximately 2-fold higher than for non-targeted liposomes (C6-Lips) at both 37 oC (Figure S3A) and 4 oC (Figure S3B), regardless of the liposome concentration. Moreover, the cellular uptake of GlcA-C6-Lips showed to be time-dependent in a period of 7 h (Figure S3C). These results confirmed our hypothesis that the modification of the Lips with a glucose analogue (GlcA) could increase the cellular uptake of the Lips by SMCs from PAs, owing to the affinity of glucose for GLUT-1 overexpressed in SMCs. 
To further investigate the endocytic pathway of the Lips in more detail, SMCs were first treated with different inhibitors to block the corresponding internalization routes, before being incubated with the C-6 labeled Lips. The uptake of both GlcA-C6-Lips and C6-Lips by SMCs were inhibited by cytochalasin-D (Cyto-D), chlorpromazine (Cpz), nocodazole and NaN3+ deoxyglucose (DG) respectively (Figure S3D & S3E), indicating that both types of Lips entered the cells in an energy-dependent way via multi-endocytic routes, including macropinocytosis, clathrin-mediated endocytosis, as well as microtubule-related internalization.
The intracellular trafficking of the Lips in SMCs was also determined. Confocal images (Figure S4) show a stronger green fluorescence intracellularly for the GlcA-C6-Lips than for C6-Lips, once again confirming the enhanced cellular uptake of the targeted Lips via the GlcA modification. Yellow punctuate fluorescence was also observed in the overlapped images after co-localization of the green fluorescence from the C6-labeled Lips with the red fluorescence from the Lyso-tracker Red stained lysosomes of SMCs, implying that the endocytosis of the Lips was lysosome-mediated. 
Pharmacokinetics, Biodistribution and Targeting to PAs in the Lungs
Following i.v. injection, the blood circulation time of the GlcA-SIL-Lips is critical for achieving targeted drug accumulation at disease site in the lung vessels. ADDIN EN.CITE 21-23 Pharmacokinetic studies of GlcA-SIL-Lips in rats showed higher plasma level of SIL after injection of the GlcA-SIL-Lips, compared to the injection of the free drug (Figure S5). Moreover, the biological half-life (t1/2), mean resident time (MRT), and area under the concentration curve (AUC) of SIL, were increased by 1-fold when injected in GlcA-SIL-Lips, while the clearance (CL) of the drug was decreased by approximately 1-fold, in contrast to the injection of the free drug (Table S2). These results indicated that the GlcA-Lips could extend the blood circulation of the drug, and thus improve the accumulation of the drug at the disease site in lung vessels.
Furthermore, ex vivo imaging was performed to investigate the biodistribution of DiR-labelled Lips in the MCT-induced model, following i.v. injection. As displayed in Figure 2, after 0.5 h and 2 h of the injection, GlcA-DiR-Lips exhibited stronger fluorescence in the lung than DiR-Lips, indicating enhanced accumulation in the lung. Additionally, following the injections of the various SIL preparations, the accumulation of SIL in different organs was quantified. SIL was found distributed in all organs after injection but the highest drug accumulation in the lung was from the GlcA-Lips (Figure S6). These results suggest the ability of GlcA-Lips to target the lung. 
To further determine the co-localization of the Lips with tunica media in the remodeled small PAs, histopathologic examination of lung sections was performed 1 day after the instillation of the IR783-labeled Lips to the MCT-induced models. As shown in Figure 3, only the IR783-GlcA-Lips were well co-localized with the remodeled PAs, implying that the GlcA modification enabled the Lips with the target capacity to the small PAs of the lung in the PAH model.
Inhibition of Vascular Remodeling and RV Hypertrophy in the MCT-induced PAH
After 2-week treatment, the PAP of MCT-induced rats was reduced to 32.4% as a result of the treatment with GlcA-SIL-Lips preparation, followed by SIL-Lips with a 26.2% decrease and free SIL with a 17.6% reduction (Figure 4A). The medial thickening of PAs was also reduced by approximately 41.3% and 20.6% with the GlcA-SIL-Lips and SIL-Lips treatment respectively, compared to the MCT-induced model group (Figure 4B & 4C). Furthermore, the treatment with GlcA-SIL-Lips led to more significant decrease in PAP and medial thickening of PAs as compared with SIL-Lips group (P <0.05). Moreover, the expression level of α-SMA in PAs of the MCT-induced models after the different treatments was evaluated, as the overexpression of α-SMA has been recognized as a marker of Proliferative PASMCs. ADDIN EN.CITE 24 Accordingly, the expression of α-SMA was down-regulated after the treatment with SIL preparations, in particular with GlcA-SIL-Lips (Figure 4D & 4E). 
RV hypertrophy is considered a key risk factor of PAH associated morbidity and mortality.  ADDIN EN.CITE 25 Therefore, the changes of RV cardiomyocyte in the MCT-induced model after the treatment with different preparations were evaluated. Histopathological examination detected significant attenuation of by the SIL-Lips, and GlcA-SIL-Lips preparation allowed for further amelioration of RV hypertrophy compared with SIL-Lips group  (P <0.05, Figure 5A), which was also confirmed in the quantitative assay (Figure 5B). Higher survival rates were also observed for rats in the group treated with SIL-Lips or GlcA-SIL-Lips preparations, with the log rank test P of 0.0416 and 0.0016 respectively, compared to the MCT-induced group without treatment (Figure 5C). 
Mechanistic Studies on the Regression of PAs in MCT-Models
After the treatment with different preparations, the proliferation of PASMCs in the PAs in rats was assessed. Both of Ki67, a cellular marker for proliferation, and caspase-3, a critical executioner for apoptosis, were used as the assessment indexes. As observed in Figure 6A, the group treated with the GlcA-SIL-Lips preparation expressed the lowest level of Ki67 among all the groups, indicating the most significant anti-proliferation effect on SMCs. Consistently, the highest expression level of caspase-3 was observed in the same group (Figure 6B).
The expression level of the phosphorylated ERK1/2 (P-ERK1/2) was also measured, as previous studies have reported the inhibition of PA remodelling with SIL treatment via down-regulating the expression of P-ERK1/2 in MCT-induced PAH. ADDIN EN.CITE ,  The expression level of a primary glycolysis initiator of SMCs, hexokinase-2 (HK-2), ADDIN EN.CITE 28 was also checked. As expected, a significant decrease on the expression of both P-ERK1/2 and HK-2 was observed after the treatment with the GlcA-SIL-Lips preparation, as shown in the immune-blotting results (Figure 6C), confirmed by the quantitative assay (Figure 6D & 6E).
In addition, both of down-regulated endothelial nitric oxide synthase (eNOS) and inactivated cGMP/cGKI signal pathway, which results from over-expression of phosphodiesterase 5 (PDE 5), induce pulmonary arterioles constriction and inhibit the apoptosis of PASMCs in PAH patients. Significantly, GlcA-SIL-Lips enabled most profound up-regulation of eNOS and cGMP among the formulations (Figures S7 and 8).
Overall, the treatment with GlcA-SIL-Lips could significantly inhibit the PA remodelling via enhanced expression of caspase-3, down-regulated expression of HK-2 and increased levels of eNOS and cGMP.

Discussion 
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Conclusion





The study demonstrates the expression of GLU-1 on PASMCs in MCT-induced PAH. Additional work is needed to investigate the possibility of the up-regulation on other cell types in PAH. Via targeting to the GLU-1 with GlcA-modified liposomes loaded SIL, the remodeling process of PAs is inhibited significantly. The platform has promising potential to be a generalized approach for PAH treatment. For translating our present finding into the clinic, more studies are warranted.
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	GLU-1 is overexpressed on PASMCs in a MCT-induced PAH experimental model. GlcA-modified nanoparticles can target to pulmonary arterioles in PAH secondary to high affinity with PASMCs.
	GlcA-SIL-Lips can effectively inhibit the proliferation and enhance the apoptosis of PASMCs, other than suppressing the right ventricle myocytes hypertrophy, which is attributed to the increased drug’s bioavailability and PASMCs targeting.
What is Relevant?
	Via targeted delivery of SIL to PASMCs using GlcA-Lips, the remodeling process of PAs as well as increased pulmonary arterial pressure is inhibited significantly via a mechanism of reduction of P-ERK1/2 and HK-2, initiation of caspase-3 related apoptotic pathway, and increased levels of eNOS and cGMP.
Summary





Figure 1. Expression level of GLUT-1 in PAs and SMCs in the MCT-induced models: (A) Echocardiographic images of the parasternal short axis views of rats and Pulsed Wave Doppler traces from the right ventricular outflow tract (RVOT) of rats. The representative changes of Pulse Wave Doppler blood flow profile of RVOT in rats, that dosed with MCT at day 0, 7, 14 and 28, displayed identical results in three independent experiments; (B) Expression level of GLUT-1 in the remodeled tunica media and PASMCs in both control and MCT-induced model groups based on the immunoblotting assay; (C) Expression level of the GLUT-1 in the remodeled PAs of rats following 28-day MCT treatment based on the immunohistochemistry assay; (D) Representative changes of increased 18-FDG uptake in the lungs and RV of rats following 28-day MCT treatment (Panel C: the yellow arrows indicate the expression of GLUT-1 in PAs; Panel D: the yellow arrow heads in the control show the uptake of 18-FDG in normal lungs and LV, whereas the white arrows show the marked increase of 18-FDG uptake in the lungs and RV of the established PAH rats.). 
Figure 2. Ex vivo fluorescence images showing the presence of DiR-loaded Lips in major organs collected from rats after 0.5 h and 2 h intravenous injections of the targeted (GlcA-DiR-Lips) and non-targeted (DiR-Lips) Lips(, with a DiR dose of 0.5 mg/kg, based on the animal’s weight.
Figure 3. Immunofluorescence images showing the co-localization of PA α-SMA with IR783-Lips (A) and GlcA-IR783-Lips (B) in the MCT-induced rats. The rats received intravenous administration of the IR783-labelled Lips at an IR783 dose of 0.5 mg/kg 4 h post-treatment, the rats’ lungs were extracted and stored in 10% formalin for fluorescent imaging. The PAs were stained in green by labelling the α-SMA with an anti–α-SMA antibody. The nuclei were stained in blue with DAPI. Yellow fluorescence indicates the co-localization.
Figure 4. Therapeutic effects of different drug and Lips formulations on pulmonary arterioles remodeling in MCT-induced rats. The rats were intravenously injected with different formulations every two days for two weeks, with a SIL dose of 8 mg/kg, according to the animal’s body weight: (A) PA pressure measured based on the RV puncture and the PA trunk catheterization of the rats in different groups (n = 7 for each group); (B) Representative changes on the medial wall thickening of PAs; (C) Quantitative analysis on the medial wall thickening of PAs; (D) Representative changes on the α-SMA expression in tunica media of PAs; (E) Quantitative analysis on the expression of α-SMA in tunica media of PAs. All data are presented as mean ± SEM (n =7). *P < 0.05, **P < 0.01 and ***P < 0.001 compared with the control group, #P < 0.05, ## P < 0.01 and ### P < 0.001 compared with the MCT-induced model group. The scale bar is 50 µm.
Figure 5. Therapeutic effects of different drug and Lips formulations on the RV cardiomyocytes’ hypertrophy and survival rates in MCT-induced rats intravenously injected with different formulations. (A) Representative morphological changes on the RV cardiomyocytes; (B) Quantitative analysis on the dimension of the RV cardiomyocytes; (C) Survival rates of rats from the different groups (n =10 for each group). All data are presented as mean ± SEM (n =7). ***P < 0.001 compared with the control group, ##P < 0.01，###P < 0.001 compared with the MCT-induced model group. The scale bar is 50 µm.
Figure 6. Expression of Ki67 (A) and Caspase-3 (B) determined by immunohistochemistry; Expression of phosphorylated ERK1/2 (P-ERK1/2) and hexokinase-2 (HK-2) analyzed by immuno-blotting (C); Density ratios of P-ERK1/2 to ERK1/2 (D) and HK-2 to β-actin (E). Panel A and B: brown spots indicate the positive. All data are presented as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control group；#P < 0.05，##P < 0.01, ###P < 0.001 compared with the MCT-induced model group. The scale bar is 50 µm.
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